IntraBio is a biopharmaceutical company focused on developing treatments for progressive neurological conditions. This page provides updates on their Levacetylleucine programme.   Levacetylleucine is a chemically modified version of the amino acid L-leucine. Amino acids […]
IntraBio and Levacetylleucine (AQNEURSA) updates Read More »
The pharmaceutical company Intrabio, who developed the recently FDA-approved drug AQNEURSA for people with Niemann-Pick Disease Type C, has announced their plans to begin a phase III trial of the
Intrabio to conduct phase III trial in SCA6 and Episodic Ataxia Type-2 Read More »
On 25th September 2024, the pharmaceutical company Intrabio announced that the FDA in the US has approved their small molecule drug Levacetylleucine for the treatment of Niemann-Pick Disease Type C
